Eli Lilly and Company (NYSE:LLY) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Eli Lilly and Company (NYSE:LLY) in a report published on Monday, Benzinga reports. They currently have a $815.00 price target on the stock. Cantor Fitzgerald also issued estimates for Eli Lilly and Company’s FY2024 earnings at $12.10 EPS.

Several other brokerages also recently weighed in on LLY. JPMorgan Chase & Co. lifted their target price on Eli Lilly and Company from $775.00 to $850.00 and gave the company an overweight rating in a research note on Friday, March 15th. Wells Fargo & Company lifted their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the company an overweight rating in a research note on Tuesday, February 6th. DZ Bank downgraded Eli Lilly and Company from a buy rating to a hold rating and set a $820.00 target price on the stock. in a research note on Wednesday, February 21st. Erste Group Bank upgraded Eli Lilly and Company from a hold rating to a buy rating in a research note on Wednesday, April 3rd. Finally, BMO Capital Markets lifted their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the company an outperform rating in a research note on Wednesday, February 7th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $728.05.

Eli Lilly and Company Trading Down 0.1 %

LLY opened at $751.20 on Monday. The firm has a market cap of $713.76 billion, a price-to-earnings ratio of 129.52, a price-to-earnings-growth ratio of 1.65 and a beta of 0.34. Eli Lilly and Company has a 52 week low of $367.35 and a 52 week high of $800.78. The business’s 50 day moving average is $762.68 and its two-hundred day moving average is $655.54. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same quarter in the previous year, the company posted $2.09 earnings per share. The firm’s revenue was up 28.1% compared to the same quarter last year. On average, research analysts predict that Eli Lilly and Company will post 12.46 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.13% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Eli Lilly and Company

A number of institutional investors have recently made changes to their positions in the stock. Versant Capital Management Inc raised its holdings in shares of Eli Lilly and Company by 1.8% in the first quarter. Versant Capital Management Inc now owns 736 shares of the company’s stock worth $573,000 after acquiring an additional 13 shares during the last quarter. Moseley Investment Management Inc. raised its holdings in shares of Eli Lilly and Company by 0.4% in the first quarter. Moseley Investment Management Inc. now owns 3,890 shares of the company’s stock worth $3,027,000 after acquiring an additional 14 shares during the last quarter. CGN Advisors LLC raised its holdings in shares of Eli Lilly and Company by 1.4% in the first quarter. CGN Advisors LLC now owns 1,001 shares of the company’s stock worth $779,000 after acquiring an additional 14 shares during the last quarter. Buckhead Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 0.7% in the fourth quarter. Buckhead Capital Management LLC now owns 2,104 shares of the company’s stock worth $1,226,000 after acquiring an additional 15 shares during the last quarter. Finally, Levin Capital Strategies L.P. raised its holdings in shares of Eli Lilly and Company by 3.8% in the fourth quarter. Levin Capital Strategies L.P. now owns 415 shares of the company’s stock worth $242,000 after acquiring an additional 15 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.